Category: Hem/Onc News
Hem/Onc News
Melphalan Approved as Liver-Directed Treatment for Uveal Melanoma On August 14, the US Food and Drug Administration (FDA) approved the use of the melphalan hepatic delivery […]
Hem/Onc News
Tisotumab Vedotin-tftv Approved for Recurrent or Metastatic Cervical Cancer On September 20, the US Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tivdak, […]
Hem/Onc News
Tepotinib Receives Accelerated Approval for Metastatic Non–Small Cell Lung Cancer On February 3, the US Food and Drug Administration (FDA) granted accelerated approval to tepotinib (Tepmetko, […]
COVID-19 in HEM/ONC News
Tocilizumab May Help Patients With COVID-19 and Myeloma The immunosuppressant tocilizumab (Actemra, Genentech) may be an effective treatment for severe coronavirus disease 2019 (COVID-19) in patients […]
Hem/Onc News
Entrectinib Approved for NTRK Fusion–Positive Solid Tumors and ROS1-Rearranged Non–Small Cell Lung Cancer On August 15, the US Food and Drug Administration (FDA) granted approval to […]
Hem/Onc News
Selinexor Approved for Multiple Myeloma On July 3, the US Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio, Karyopharm) in combination with dexamethasone […]
Hem/Onc News
Tagraxofusp-erzs Approved in Blastic Plasmacytoid Dendritic Cell Neoplasm The US Food and Drug Administration (FDA) approved tagraxofusp-erzs (Elzonris, Stemline) on December 21 for blastic plasmacytoid dendritic […]
Hem/Onc News
Duvelisib Approved in Relapsed/Refractory CLL, SLL, and FL The US Food and Drug Administration (FDA) approved duvelisib (Copiktra, Verastem) on September 24 for adults with relapsed […]
Hem/Onc News
Pembrolizumab Receives Regular Approval in Metastatic Nonsquamous NSCLC On August 20, the US Food and Drug Administration (FDA) granted regular approval to pembrolizumab (Keytruda, Merck) for […]
Hem/Onc News
Ivosidenib Approved for Relapsed or Refractory Acute Myeloid Leukemia On July 20, the US Food and Drug Administration (FDA) approved ivosidenib (Tibsovo, Agios) for adults with […]
Hem/Onc News
First Biosimilar to Pegfilgrastim Approved to Decrease Risk for Infection During Cancer Treatment On June 4, the US Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila, […]
Hem/Onc News
Osimertinib Approved for First-Line Treatment in Metastatic NSCLC On April 18, the US Food and Drug Administration (FDA) approved osimertinib (Tagrisso, AstraZeneca) for the first-line treatment […]
Hem/Onc News
Rucaparib Approved for Maintenance Treatment in Recurrent Ovarian Cancer On April 6, the US Food and Drug Administration (FDA) approved rucaparib (Rubraca, Clovis Oncology) for maintenance […]
Hem/Onc News
Apalutamide Approved for Use in Nonmetastatic Castration-Resistant Prostate Cancer The US Food and Drug Administration (FDA) on February 14 approved the next-generation androgen receptor inhibitor apalutamide […]
Hem/Onc News
Axicabtagene, Second CAR T-Cell Therapy, Approved in Lymphoma The US Food and Drug Administration (FDA) approved the T-cell therapy axicabtagene ciloleucel (Yescarta, Kite) on October 18 […]
Hem/Onc News
Abemaciclib Approved in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer On September 28, the US Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Lilly) as a […]
Hem/Onc News
First Gene Therapy Approved for Use in Acute Lymphoblastic Leukemia The US Food and Drug Administration (FDA) has approved tisagenlecleucel (Kymriah, Novartis), the first chimeric antigen […]
Hem/Onc News
Recombinant Factor IX Approved for Use in Adults and Children With Hemophilia B The US Food and Drug Administration (FDA) approved the recombinant coagulation factor IX […]
News
Clinical Advances in Hematology & Oncology April 2017, Volume 15, Issue 4 By Devon Schuyler Pembrolizumab Improves Survival in Advanced Urothelial Cancer Pembrolizumab (Keytruda, Merck) improved […]
Hem/Onc News
Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Devon Schuyler Daratumumab Improves Progression-Free Survival in Relapsed/Refractory Myeloma The addition of daratumumab (Darzalex, […]